硫氧还蛋白还原酶在恶性肿瘤诊断、疗效预测及预后中的应用  

Application of thioredoxin reductase in the diagnosis,prognosis, and prediction of malignant tumors

作　　者：王园园 闵茜 郑忠亮 姚颐[1,3] WANG Yuanyuan;MIN Qian;ZHENG Zhongliang;YAO Yi(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China;State Key Laboratory of Virology,Cllege of Life Sciences,Wuhan University,Wuhan 430072,China;Hubei Provincial Research Center for Precision Medicine of Cancer,Wuhan 430200,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060 [2]武汉大学生命科学学院,病毒学国家重点实验室,武汉430072 [3]湖北省肿瘤精准医学研究中心,武汉430200

出　　处：《生命的化学》2024年第4期614-620,共7页Chemistry of Life

基　　金：湖北省自然科学基金一般项目(2022CFB114)。

摘　　要：理想的肿瘤标志物应当具有较好的灵敏度和特异性。硫氧还蛋白还原酶(thioredoxin reductase,TrxR)是一种广泛存在于生物体内的重要酶类,其主要功能是将被氧化的硫氧还蛋白还原成有活性的形式。研究已证实,TrxR与某些恶性肿瘤的发展、复发和不良预后密切相关,在肿瘤的早期诊断、复发监测和疗效预测等方面均具有潜在价值。本文就近年来TrxR在恶性肿瘤筛查、诊断、疗效预测以及患者预后中的应用及其相关研究展开综述,为该指标广泛运用于临床提供理论依据。An optimal tumor biomarker should have high sensitivity and specificity. Thioredoxin reductase(TrxR) is a crucial enzyme found in living organisms, primarily responsible for converting oxidized thioredoxin into its active form. Numerous studies have revealed a strong correlation between TrxR and the progression, recurrence, and poor prognosis of certain malignant tumors. It suggests that TrxR could be useful in identifying tumors early, monitoring recurrence, and predicting treatment efficacy. This review presents a detailed summary of recent developments in the use of TrxR for cancer screening, diagnosis, treatment efficacy prediction, and patient prognosis assessment to provide a theoretical basis for the widespread integration of TrxR into clinical practice.

关 键 词：硫氧还蛋白还原酶 恶性肿瘤 生物标志物 诊断 预测 预后 

分 类 号：R730.43[医药卫生—肿瘤]